News-Events

CBI e-Newsletter/CBI Report

Collaborative Innovation > Transformational Impact

October 2007 - Vol 2, Issue 3

In This Issue

• CBI Leadership Transition Moving Ahead
• CBI Events Calendar
• Research Highlights
• Recent CBI Publications

Join our Mailing List

View Newsletter Archive

The summer was a busy and exciting time for us at CBI. We have refined our Research Portfolio, launched our new Biomanufacturing TRP, increased awareness of CBI's activities through an internal outreach campaign across MIT, and established a tighter operating model for the organization. I want to especially thank Claude Canizares, VP of Research and Associate Provost, as well as all the Council members and faculty who generously shared their time and input in our Strategic Planning Process. Among the key things these discussions highlighted for us was the importance of CBI's Safe Haven model for breakthrough collaborative innovation, and a strong desire to leverage lessons learned from other industries. Over the next few months, we look forward to announcing a number of new programs for 2008 that will focus on themes that emerged from our increased outreach efforts. We know you'll be interested in them — so stay tuned. Regards, Gigi Hirsch Interim Executive Director

 

I am so pleased with the progress we have made at CBI in the past few months. Thanks to the hard work of Gigi Hirsch, Sherene Aram, Cheryl Mottley, and my co-directors, Ernie Berndt and Steve Tannebaum--not to mention the outstanding guidance and help from many of our Council members and other faculty--we are building a whole new foundation for CBI that I believe will have tremendous payoffs for everyone. I believe CBI plays an important role within the MIT universe. Working with colleagues from business management and bioengineering in an interdisciplinary effort, and partnering with thought leaders and practitioners in industry and government, creates a rich field for progress and innovation that is hard to match anywhere. I'm particularly gratified by the opportunities we provide for students, whose involvement in hands-on research and help in finding real world solutions to complex problems are preparing them in ways that will make them uniquely equipped to handle the challenges of the future. (You can read some of their outstanding work in our Publications section below). We are truly preparing the next generation of leaders that will move healthcare innovation and improvement to new heights. I invite you to join with me and my colleagues in an exciting and enriching endeavor at CBI. Regards, Tony Sinskey Faculty Co-Director

CBI CALENDAR

October 18, 2007: CBI Strategy and Policy Council Teleconference

October 30, 2007: Dr. Martin Mackay lecture (see below)

November 2007 (TBA): Biomanufacturing Steering Committee Meeting

Upcoming 2008 CBI events will be listed in the next CBI Update.

Dr. Martin Mackay, President Global R&D, Pfizer to Lecture-Oct. 30th

CBI, along with the MIT Sloan Biomedical Club and Sloan Fellow Program, wil co-sponsor a lecture by Dr. Martin Mackay, President Global R&D at Pfizer, Inc. Dr. Mackay will speak on: "In-House vs. In-Licensing: Is there a need to balance in-house R&D with in-licensing and partnering?" The program will be moderated by Professor Fiona Murray, Class of 1922 Career Development Professor, Associate Professor Management of Technology Innovation & Entrepreneurship.

October 30,2007
12-12:50 p.m.
70 Memorial Drive
Room E51-345, Cambridge

Spring '08: Watch for another lecture in this series by Dr. Roger Perlmutter, EVP, R&D, Amgen

CBI RESEARCH HIGHLIGHTS

CBI's Research Portfolio is focusing on Transformational Research Programs, Projects and Issues Analyses that have emerged from our Strategic Planning process.

Biomanufacturing TRP: Steering Committee launched; BioPAT Applied case-study based knowledge and learning management software system under development in partnership with MIT's Center for Collective Intelligence. Contact Elizabeth Bruce, ej_bruce@mit.edu.

Streaminlining Clinical Trial Operations: Optimizing Trial Design: Draft working paper, "The Future of Drug Development: Clinical Trial Design," currently under review by the FDA. Contact Gigi Hirsch, ghirsch@mit.edu.

Enhancing Collaborative Innovation: Success Drivers and Barriers of Bioclusters: Student thesis completed with generous support from Kauffman Foundation grant. Includes analysis of success factors for Singapore and San Diego bioclusters. Additional analysis of Boston biocluster now underway, to be completed 12/07. Contact Gigi Hirsch, ghirsch@mit.edu.

R&D Productivity TRP: Program scope and initial projects currently under discussion; plan TBA in next CBI newsletter. Contact Ken Fasman, kfasman@mit.edu.

Click here to see an updated look at our Full Research Portfolio.  

CBI Publications

CBI has a growing list of publications, white papers, and masters theses on a variety of research topics conducted by CBI researchers and affiliates.

Please visit the Publications section of our website to view recent publications, including:

Theses:

• Changes in the Characteristics of Approved New Drug Applications for Antihyperintensives
  
• Assessing Decision Inputs in Drug Development between Small, Early Stage Companies and Big Pharma: Is There a Difference?Mergers and Acquisitions in the Medical Device Industry
  
• Assessing the Economic Case for Stratified Medicine

White Papers:

• The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Refocoxib and Celecoxib with Myocardial Infarction (Brownstein, Sordo, Kohane, Mandl) (PDF)
• The December Effect in FDA Drug Approvals: Assessing the Submissions Echo Hypothesis (Graham, Berndt) (PDF)

Center for Biomedical Innovation

email: mottley@mit.edu
phone: (617) 253-0257
web: http://web.mit.edu/cbi